52 results
8-K
EX-99.1
CLVSQ
Clovis Oncology, Inc.
3 Jun 13
Clovis Oncology’s CO-1686 Demonstrates Encouraging Results from Ongoing Phase I/II Study in EGFR-mutant Non-Small Cell Lung Cancer
12:00am
reached.
"The oncology community has been working to develop successful treatments for EGFR mutant patients with acquired resistance to erlotinib … community."
“There are no approved treatment options for patients with non-small cell lung cancer who have developed the T790M resistance mutation,” said
8-K
EX-10.2
CLVSQ
Clovis Oncology, Inc.
4 Jun 20
Departure of Directors or Certain Officers
4:06pm
are to be registered must sign this Notice of Exercise. (If more than one name is listed, specify whether the owners will hold the Shares as community property or as joint tenants with the right of survivorship).
-6-
424B3
CLVSQ
Clovis Oncology, Inc.
2 Dec 13
Prospectus supplement
12:00am
the oncology community is increasingly recognizing that tumors in a particular organ have unique pathologic and molecular characteristics that may … are not and were not affiliated with registered broker-dealers.
S-8
Subject to community property laws where applicable, we believe based
424B3
CLVSQ
Clovis Oncology, Inc.
4 Dec 13
Prospectus supplement
12:00am
and minimal effect on overall survival. We believe the oncology community is increasingly recognizing that tumors in a particular organ have unique … or affiliates, other than EOS, and the selling stockholders are not and were not affiliated with registered broker-dealers.
S-8
Subject to community property
8-K
EX-99.1
rfpfq
8 Aug 22
Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
8:01am
10-Q
x2a3nzuy0njjpb 39cy
11 May 12
Quarterly report
12:00am
424B5
47451u jz8ioalphbt0
12 Jun 13
Prospectus supplement for primary offering
12:00am
424B5
zu1bs84nx556zi6xv8m
12 Jun 13
Prospectus supplement for primary offering
12:00am
424B5
fqxm npbvz
10 Jun 13
Prospectus supplement for primary offering
12:00am
10-K
gtx9r8wc153kb
15 Mar 12
Annual report
12:00am
424B1
w2tjxh1l1dig
4 Apr 12
Prospectus with pricing info
12:00am
S-1
4q7035j8fgho 7mi
23 Jun 11
IPO registration
12:00am